| Literature DB >> 34885036 |
Holly E L Evans1, Daniel A Galvão2, Cynthia C Forbes3, Danielle Girard4, Corneel Vandelanotte5, Robert U Newton2,6, Andrew D Vincent1, Gary Wittert1, Ganessan Kichenadasse7, Suzanne Chambers2,8, Nicholas Brook9, Camille E Short1,10,11.
Abstract
Preliminary research has shown the effectiveness of supervised exercise-based interventions in alleviating sequela resulting from metastatic prostate cancer. However, many individuals encounter barriers that limit the uptake of face-to-face exercise. Technology-enabled interventions offer a distance-based alternative. This pilot study aimed to explore the acceptability, safety and preliminary efficacy of a web-based exercise intervention (ExerciseGuide) in individuals with metastatic prostate cancer. Forty participants (70.2 ± 8.5 years) with metastatic prostate cancer were randomised into the 8-week intervention (N = 20) or a wait-list control (N = 20). The intervention arm had access to a computer-tailored website, personalised exercise prescription and remote supervision. ExerciseGuide was deemed acceptable with a score ≥20 on the client satisfaction questionnaire; however, the usability score was just below the pre-specified score of ≥68 on the software usability scale. There were no serious adverse events reported. Moderate-to-vigorous physical activity levels between baseline and follow-ups were significantly higher (10.0 min per day; 95% CI = (1.3-18.6); p = 0.01) in the intervention group compared to wait-list control. There were also greater improvements in step count (1332; 95% CI = (159-2505); p = 0.02) and identified motivation (0.4, 95% CI = (0.0, 0.7); p = 0.04). Our findings provide preliminary evidence that ExerciseGuide is acceptable, safe and efficacious among individuals with metastatic prostate cancer.Entities:
Keywords: acceptability; behavioural change; computer-tailoring; eHealth; exercise; metastatic prostate cancer; rct; usability
Year: 2021 PMID: 34885036 PMCID: PMC8656540 DOI: 10.3390/cancers13235925
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Screenshots of the ExerciseGuide intervention: (a) the ExerciseGuide landing page, (b) the ExerciseGuide homepage, (c) the My Exercise Plan 1 module (d) the Making it Last (behaviour change) module.
Figure 2Participant flow chart.
Figure 3Website usage in the ExerciseGuide intervention group: (a) time spent on website per week and (b) number of logins per week.
Participant characteristics for the whole sample at baseline (N = 40).
| Characteristics | Intervention | Control | Total | |
|---|---|---|---|---|
| Age, mean ± SD, year | 69.5 ± 6.6 | 70.8 ± 10.2 | 70.2 ± 8.5 | |
| Weight, mean ± SD, kg | 95.9 ± 20.8 | 90.0 ± 17.1 | 92.9 ± 19.0 | |
| Body Mass Index, mean ± SD, kg/m2 | 30.5 ± 5.2 | 28.7 ± 5.2 | 29.6 ± 5.3 | |
| Marital status, | Married/de facto | 15 (75.5%) | 13 (61.9%) | 28 (68.3%) |
| Widowed | 1 (5.0%) | 2 (9.5%) | 3 (7.3%) | |
| Separated | 4 (20.0%) | 2 (9.5%) | 6 (14.6%) | |
| Single | 0 (0.0%) | 4 (19.0%) | 4 (9.8%) | |
| Location, | Major city | 12 (60.0%) | 14 (66.7%) | 26 (63.4%) |
| Inner regional | 5 (25.0%) | 4 (19.0%) | 9 (22.0%) | |
| Outer regional | 1 (5.0%) | 3 (14.3%) | 4 (9.8%) | |
| Remote or very remote | 2 (10.0%) | 0 (0.0%) | 2 (4.8%) | |
| Education, | Secondary School | 2 (10.0%) | 8 (38.1%) | 10 (24.4%) |
| Trade/TAFE | 11 (55.0%) | 5 (23.8%) | 16 (39.0%) | |
| University/Other Tertiary | 7 (35.0%) | 8 (38.1%) | 15 (36.6%) | |
| Employment, | Employed full-time | 1 (5.0%) | 2 (9.5%) | 3 (7.3%) |
| Employed part-time | 1 (5.0%) | 2 (9.5%) | 3 (7.3%) | |
| Self-employed | 0.0 (0%) | 3 (14.3%) | 3 (7.3%) | |
| Unemployed | 2 (10.0%) | 1 (4.8%) | 3 (7.3%) | |
| Retired | 16 (80.0%) | 13 (61.9%) | 29 (70.8%) | |
| Current treatment, | Surgery | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Radiotherapy | 2 (10.0%) | 2 (9.5%) | 4 (9.8%) | |
| Chemotherapy | 6 (30.0%) | 7 (9.5%) | 13 (31.7%) | |
| Hormone therapy | 19 (90.0%) | 19 (90.5%) | 38 (92.7%) | |
| Previous treatment, | Surgery | 8 (40.0%) | 5 (23.8%) | 13 (31.7%) |
| Radiotherapy | 9 (45.0%) | 10 (47.6%) | 19 (46.3%) | |
| Chemotherapy | 9 (45.0%) | 14 (66.7%) | 23 (56.1%) | |
| Hormone therapy | 1 (5.0%) | 1 (5.0%) | 2 (9.5%) | |
| Current PSA, mean ± SD, | 15.2 ± 31.9 | 10.2 ± 38.7 | 12.5 ± 35.2 | |
| Time since metastatic disease diagnosis, mean ± SD, years | 3.5 ± 3.1 | 2.57 ± 3.1 | 3.0 ± 3.1 | |
| Number of individuals with ≥1 bone lesion, | 15 (75.0%) | 18 (85.7%) | 33 (80.5%) | |
| Number of co-morbidities, mean ± SD | 1.5 ± 1.6 | 2.0 ± 1.6 | 1.7 ± 1.6 | |
Abbreviations: SD, standard deviations; N, number; PSA, prostate specific androgen.
ExerciseGuide website usage within the intervention group (N = 20).
| Module Name | Percentage of Modules Viewed | Average Total Time in Module per Participant (mins) | Average Total Page Views | Star Ratings | |||||
|---|---|---|---|---|---|---|---|---|---|
| (%) | ( | (M) | (SD) | (M) | (SD) | (Median) | (Range) | ( | |
| Introduction | 100% | 20 | 2.4 | 2.3 | 6.7 | 4.5 | Nil | Nil | 0 |
| Exercise plan (Week 1–3) | 100% | 20 | 19.5 | 21.0 | 18.9 | 13.4 | 4.0 | 4.0–4.0 | 3 |
| Exercise plan (Week 4–8) | 65% | 13 | 5.2 | 6.0 | 5.7 | 6.0 | 3.0 | 3.0–3.0 | 1 |
| Exercise benefits | 75% | 15 | 2.0 | 1.0 | 3.7 | 2.5 | 4.0 | 4.0–5.0 | 4 |
| Exercise safely | 60% | 12 | 4.0 | 3.0 | 1.5 | 1.5 | 4.5 | 4.0–5.0 | 6 |
| Make it last | 55% | 11 | 1.5 | 1.3 | 2.0 | 2.2 | 4.0 | 4.0–5.0 | 3 |
| Exercise+ (lifestyle) | 50% | 10 | 4.3 | 3.4 | 1.3 | 1.6 | 4.0 | 4.0–4.0 | 2 |
| Extra help | 45% | 9 | 1.3 | 1.3 | 1.2 | 1.4 | 4.0 | 4.0–5.0 | 3 |
| Weekly tracking module 1 | 65% | 13 | 3.1 | 2.2 | 3.0 | 2.7 | 3.0 | 1.0–5.0 | 5 |
| Weekly tracking module 2 | 25% | 5 | 2.0 | 1.1 | 0.7 | 1.2 | 2.5 | 2.0–3.0 | 2 |
| Weekly tracking module 3 | 10% | 2 | 1.2 | 1.1 | 0.2 | 0.7 | 2.0 | 4.0–4.0 | 4 |
Racking modules were available weekly. Tracking modules 4–8 were completed by 0% (N = 0) of the ExerciseGuide intervention group.Abbreviations: N, number; M, mean; SD, standard deviations.
Group differences in physical activity measures over the course of the intervention.
| Outcome | Baseline | Follow-Up | Adjusted Mean Differences | |||
|---|---|---|---|---|---|---|
| EG ( | CON ( | EG ( | CON ( | M (95% CI) | ||
| MVPA (min/day) | 30.57 ± 22.0 | 38.4 ± 22.2 | 35.1 ± 23.6 | 32.0 ± 22.7 | 10.0 (1.3, 18.6) | 0.01 * |
| Sedentary activity (min/day) | 668.1 ± 171.0 | 708.7 ± 66.5 | 693.6 ± 117.1 | 731.0 ± 66.5 | −33.46 (−95.0, 28.1) | 0.63 |
| Steps (steps/day) | 4977 ± 3146 | 6169 ± 3001 | 5885 ± 3071 | 5556 ± 3141 | 1332 (159, 2505) | 0.02 * |
| Light PA (min/week) | 469.5 ± 206.9 | 561.6 ± 159.8 | 544.9 ±230.4 | 526.2 ± 199.3 | 96.7 (−5.4, 198.8) | 0.10 |
| Moderate PA (min/week) | 203.0 ± 149.7 | 256.9 ± 150.0 | 232.7 ± 158.8 | 208.6 ± 142.3 | 69.9 (15.1, 124.8) | 0.01 * |
| Vigorous PA (min/week) | 11.0 ± 14.1 | 13.4 ± 13.3 | 12.0 ± 16.0 | 15.6 ± 21.1 | 1.9 (−12.4, 8.5) | 0.88 |
| GLTEQ (aerobic) | 37.9 ± 37.7 | 40.6 ± 29.2 | 52.3 ± 38.8 | 36.7 ± 28.0 | 16.9 (−0.5, 33.8) | 0.07 |
| Resistance training frequency (sessions/week) | 1.4 ± 2.0 | 1.2 ± 1.8 | 2.3 ± 3.6 | 1.8 ± 2.0 | 0.5 (−0.8, 1.6) | 0.90 |
| Resistance training duration (min) | 10.8 ± 17.9 | 14.0 ± 20.3 | 22.4 ± 18.2 | 12.5 ± 17.3 | 10.3 (−1.2, 21.7) | 0.08 |
| Resistance training RPE | 0.4 ± 0.8 | 0.6 ±0.1 | 6.2 ± 18.9 | 4.2 ± 3.0 | 2.1 (0–0.4, 3.9) | 0.13 |
Abbreviations: EG, ExerciseGuide group; CON, Control group; PA, Physical activity; GLTEQ, Godin leisure time questionnaire; RPE, rate of perceived exertion. * Indicates significant values (p < 0.05).
Group differences in patient-reported outcome measures over the course of the intervention.
| Outcome | Baseline | Follow-Up | Mean Difference | |||
|---|---|---|---|---|---|---|
| EG | CON | EG | CON | M (95% CI) | ||
| Quality of life (EORTC QLQ-C30) | ||||||
| Global Health status 1 | 62.7 ± 22.3 | 71.9 ± 15.0 | 68.4 ± 22.0 | 64.5 ± 22.2 | 9.3 (−3.7–22.4) | 0.24 |
| Functional status 2 | ||||||
| Physical functioning | 84.1 ± 16.2 | 90.9 ± 12.0 | 85.9 ± 17.4 | 87.0 ± 12.5 | 4.1 (−2.8–10.9) | 0.44 |
| Role functioning | 84.2 ± 22.5 | 82.5 ± 18.0 | 82.5 ± 26.9 | 75.4 ± 28.5 | 5.2 (−10.6–21.0) | 0.37 |
| Emotional functioning | 86.8 ± 10.9 | 86.4 ± 16.2 | 84.6 ± 13.4 | 84.2 ± 18.4 | −0.2 (−8.1–7.6) | 0.86 |
| Cognitive functioning | 77.2 ± 18.6 | 85.1 ± 13.5 | 77.2 ± 18.6 | 81.6 ± 12.5 | 0.3 (−9.3–9.8) | 0.81 |
| Social functioning | 78.9 ± 22.1 | 74.6 ± 21.1 | 80.7 ± 21.7 | 70.2 ± 27.0 | 8.4 (−5.7–22.6) | 0.63 |
| Symptom Scales 3 | ||||||
| Fatigue | 36.3 ± 20.2 | 31.6 ± 21.7 | 39.8 ± 19.4 | 38.0 ± 23.0 | 2.5 (−7.2–12.2) | 0.56 |
| Nausea/Vomiting | 3.5 ± 11.9 | 1.8 ± 7.6 | 0.9 ± 3.8 | 3.5 ± 8.9 | −3.4 (−7.6–0.9) | 0.22 |
| Insomnia | 36.8 ± 27.0 | 24.6 ± 24.4 | 36.8 ± 6.7 | 29.8 ± 29.2 | −1.3 (−13.9–26.2) | 0.27 |
| Pain | 21.1 ± 24.7 | 14.9 ± 19.2 | 24.6 ± 25.1 | 21.9 ± 26.7 | −0.5 (−15.5–14.5) | 0.81 |
| Dyspnoea | 14.0 ± 16.9 | 15.8 ± 17.1 | 15.8 ± 20.4 | 19.3 ± 16.9 | −2.6 (−14.4–9.2) | 0.40 |
| Appetite loss | 10.5 ± 15.9 | 1.8 ± 7.6 | 5.3 ± 16.7 | 12.8 ± 27.7 | −11.7 (−27.5–27.5) | 0.18 |
| Diarrhoea | 3.5 ± 15.3 | 5.3 ± 13.0 | 5.2 ± 12.5 | 13.0 ± 20.3 | −7.7 (−19.0–3.5) | 0.22 |
| Constipation | 3.5 ± 10.5 | 8.8 ± 18.7 | 7.0 ± 23.8 | 3.5 ± 10.5 | 0.5 (−1.0–2.0) | 0.49 |
| Financial difficulties | 15.8 ± 23.2 | 10.5 ± 19.4 | 7.1 ± 17.8 | 14.0 ± 27.9 | −9.6 (−23.9–4.6) | 0.26 |
| Fatigue (FACIT-F) 4 | 37.7 9.6 | 41.4 ± 6.5 | 38.4 ± 15.0 | 37.9 ± 12.4 | 5.3 (−0.4–11.1) | 0.06 |
| Depression (HADS-D) 5 | 3.3 ± 3.1 | 2.9 ± 1.9 | 3.1 ± 2.8 | 4.1 ± 2.3 | −1.3 (−2.4–−2.4) | 0.06 |
| Anxiety (HADS-A) 5 | 2.9 ± 3.2 | 4.4 ± 2.7 | 3.2 ± 3.4 | 4.7 ± 3.3 | −0.2 (−1.7–1.2) | 0.74 |
| Sleep Index (PSQI) 6 | 7.2 ± 2.9 | 6.9 ± 3.3 | 11.5 ± 3.7 | 10.7 ± 3.1 | 0.6 (−1.4–2.6) | 0.10 |
1 Global health status/quality of life score ranged from 0–100, with a higher score representing a higher quality of life. 2 Scores for the functional scales ranged from 0–100, with a higher score representing a high level of functioning. 3 Scores for the symptom item ranged from 0–100, and a higher score represents a higher level of symptomatology/problems. 4 FACIT-fatigue, all items were summed to create a single fatigue score ranging from 0 to 52, with higher scores representing better functioning or less fatigue. 5 Hospital anxiety and depression scale score provides two subscale scores (HADS-D) and (HADS-A). A score greater than seven denotes anxiety or depression. 6 The PSQI total score can range from 0 to 21. A global score of five or more indicates poor sleep quality, the higher the score, the worse the sleep quality. Abbreviations: EG, ExerciseGuide group; CON, Control group.
Differences in mechanisms of action by group at baseline and follow-up (N = 40).
| Outcome | Baseline | Follow-Up | Adjusted Change Mean Difference (95% CI) | |||
|---|---|---|---|---|---|---|
| EG | CON | EG | CON | |||
| Self-efficacy 1 | ||||||
| Barrier (aerobic) sum | 36.2 ± 8.6 | 36.7 ± 6.7 | 33.5 ± 8.7 | 36.3 ± 5.7 | −3.9 (−8.2, 0.3) | 0.07 |
| Barrier (resistance) sum | 35.6 ± 8.6 | 35.8 ± 6.7 | 33.1 ± 7.7 | 36.5 ± 5.2 | −3.50 (−10.7, 2.3) | 0.08 |
| Outcome expectations 2 | ||||||
| Sum | 31.9 ± 4.0 | 31.4 ± 4.3 | 32.3 ± 4.5 | 31.7 ± 3.5 | 0.23 (−1.5, 2.0) | 0.79 |
| Motivation type 3 | ||||||
| Amotivation | 0.6 ± 0.7 | 0.4 ± 0.8 | 0.3 ± 0.7 | 0.4 ± 0.5 | −0.1 (−0.5, 0.2) | 0.40 |
| External regulation | 0.9 ± 0.9 | 0.9 ± 1.0 | 0.6 ± 0.6 | 0.8 ± 1.0 | −0.1 (−0.6, 0.3) | 0.54 |
| Introjected regulation | 1.6 ± 1.2 | 1.9 ± 1.2 | 1.5 ± 1.0 | 1.9 ± 1.3 | −0.1 (−0.6, 0.5 | 0.59 |
| Identified regulation | 2.6 ± 0.7 | 3.1 ± 0.7 | 2.8 ± 0.7 | 2.9 ± 0.9 | 0.4 (0.0, 0.7) | 0.04 * |
| Intrinsic regulation | 2.0 ± 1.1 | 2.7 ± 0.8 | 2.3 ± 0.9 | 2.5 ± 0.8 | 0.3 (0.0, 0.7) | 0.07 |
| Social support 4 | ||||||
| Sum | 7.7 ± 2.3 | 6.7 ± 2.6 | 6.9 ± 2.2 | 7.4 ± 2.1 | −1.0 (−2.5, 0.3) | 0.14 |
| Intention 5 | ||||||
| Aerobic intention strength | 68.2 ± 27.1 | 67.7 ± 22.3 | 62.4 ± 27.7 | 68.4 ± 19.3 | −7.2 (−20.8, 6.4) | 0.29 |
| Resistance intention strength | 64.8 ± 31.9 | 66.6 ± 37.7 | 54.8 ± 30.6 | 67.3 ± 25.9 | −14.7 (−30.5, 1.1) | 0.06 |
| Behavioural capability | ||||||
| Aerobic training experience 6 | 2.5 ± 1.3 | 3.4 ± 0.8 | 3.0 ± 1.0 | 3.2 ± 0.9 | 0.2 (−0.4, 0.8) | 0.47 |
| Resistance training experience 6 | 1.7 ± 1.4 | 2.1 ± 1.3 | 1.7 ± 1.3 | 1.8 ± 1.4 | 0.2 (−0.3, 0.9) | 0.37 |
| Falls confidence 7 | 3.0 ± 0.7 | 3.0 ± 1.1 | 2.9 ± 1.2 | 2.9 ± 1.1 | 0.0 (−1.1, 0.4) | 0.39 |
| Habit formation 8 | ||||||
| Sum | 12.9 ± 6.3 | 16.8 ± 6.1 | 13.8 ± 6.7 | 17.1 ± 6.1 | −1.2 (−4.9, 2.3) | 0.47 |
1 Barrier self-efficacy consisted of nine items which were scored from one (not very confident at all) to five (very confident) and the barrier self-efficacy sum is the summation of all nine item scores (ranging from 5–45). 2 Outcome expectation consisted of eight items which were scored from one (strongly disagree) to five (strongly agree) and outcome expectation sum is the summation of all eight item scores (ranging from 5–40). 3 Motivation type was determined by the Behavioural Regulations in Exercise Questionnaire (BREQ). Items were scored from one (not true for me) to five (very true for me). The mean score was calculated for every sub-item and scores range from 0–5. 4 Social support was the summation of two items (ranging from 2–14), which were scored from one (strongly disagree) to seven (strongly agree). 5 Intention was determined on a scale of 0 (no intention to exercise) to 100 (full intention to exercise). 6 Exercise experience for both aerobic and resistance training was scored on a scale of one (not true for me) to five (very true for me). 7 Confidence of not falling within the next 12 months was scored on a scale of one (not true for me) to five (very true for me). 8 Habit formation consisted of four items which were from one (strongly disagree) to five (strongly agree) and the habit formation sum is the summation of all four item scores (ranging from 5–20). * Indicates significant values (p < 0.05).